Skip to content

The Therapeutic Potential of Psychedelic-assisted Therapies for Symptom Control in Patients Diagnosed With Serious Illness: A Systematic Review

Lucas Oliveira Maia, Yvan Beaussant, Ana Cláudia Mesquita Garcia

Journal of Pain and Symptom Management February 11, 2022 DOI: 10.1016/j.jpainsymman.2022.01.024 via OpenAlex

Summary

AI-generated from the abstract

A systematic review of 20 studies found that psychedelic-assisted therapies show positive effects for symptom control in patients with serious illness, particularly for psychological and spiritual symptoms. Most studies used lysergic acid diethylamide, psilocybin, or N,N-dipropyltryptamine in cancer patients. Adverse effects were physical or psychological, mild to moderate, transient, and self-resolving. The evidence suggests considerable safety of use.

Study at a glance

Characteristics Systematic review Randomized Peer reviewed
Sample size 20
Population Patients diagnosed with serious illness
Topics Psilocybin
Keywords Cinahl Psycinfo Medline Psychosocial
Citations 59
Key finding Psychedelic-assisted therapies show positive effects for symptom control in patients with serious illness, especially for psychological and spiritual symptoms.

Abstract

ContextPeople affected by serious illness usually experience suffering in its various dimensions, not only in the physical but also in the psychosocial and spiritual aspects. The interest in psychedelic-assisted therapies as a potential new therapeutic modality has increased since evidence suggests a significant impact of their use on the outcomes of patients with serious illness.ObjectivesTo systematically review the available evidence on the effects of psychedelic-assisted therapies for symptom control in patients diagnosed with serious illness.MethodsThe protocol of this systematic review has been prepared according to the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols guidelines. This review included randomized and non-randomized controlled trials published in peer-reviewed scientific journals. A comprehensive search for studies was carried out in the main scientific databases, including Web of Science, Scopus, Cochrane Library, PsycINFO, PubMed, CINAHL, and EMBASE. There were no limitations regarding the year or language of publication.ResultsThe sample was composed of 20 studies. The results suggest positive effects of psychedelic-assisted therapies for symptom control in patients diagnosed with serious illness, with considerable safety of use. Most studies have been conducted with lysergic acid diethylamide, psilocybin, and N,N-dipropyltryptamine in cancer patients. The adverse effects reported were of physical and/or psychological nature and of mild to moderate intensity, transient, and self-resolutive.ConclusionThe evaluated evidence suggests positive effects of psychedelic-assisted therapies for symptom control in patients diagnosed with serious illness, especially regarding symptoms of psychological and spiritual nature.

Explore topics

Comments

No comments yet.

Log in to comment